Zymeworks Inc.
ZYMENext catalyst
Futibatinib
Biliary Tract Neoplasms
Get an email about ZYME's next catalysts
Track Zymeworks (ZYME) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Futibatinib Phase 3 Est. Readout (SAFIR-ABC10)
Estimated primary completion for Futibatinib trial (NCT05615818) in Biliary Tract Neoplasms. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
WebsiteFutibatinib
Biliary Tract Neoplasms
Zanidatamab
Breast Cancer
Ivosidenib
Biliary Tract Neoplasms
Ampreloxetine
Symptomatic Neurogenic Orthostatic Hypotension
ZW25
Endometrial Cancer
TD-1211
Opioid Induced Constipation
TD-9855
Attention-Deficit/Hyperactivity Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Futibatinib | Phase 3 | Biliary Tract Neoplasms | - | - |
Zanidatamab | Phase 3 | Breast Cancer | - | - |
Ivosidenib | Phase 3 | Biliary Tract Neoplasms | - | - |
Ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension | - | - |
ZW25 | Phase 2 | Endometrial Cancer | - | - |
TD-1211 | Phase 2 | Opioid Induced Constipation | - | - |
TD-9855 | Phase 2 | Attention-Deficit/Hyperactivity Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Zymeworks Inc.'s drug pipeline?β
CatalystAlert tracks 7 drug candidates in Zymeworks Inc.'s (ZYME) pipeline across Phase 3, Phase 2. Its lead program is Futibatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zymeworks Inc.'s next FDA catalyst?β
Zymeworks Inc.'s (ZYME) next tracked catalyst is a Phase 3 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZYME biotech catalysts?β
Add ZYME to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zymeworks Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
